Tracking cancer drug performance in everyday russian hospitals

NCT ID NCT04746950

Ongoing Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study observes how patients with chronic lymphocytic leukemia (CLL) respond to the drug acalabrutinib during routine treatment in Russian hospitals. Researchers will track 90 adult patients who recently started this medication to understand how well it works and what side effects occur in real-world settings. The study collects data from normal doctor visits without changing treatment plans, aiming to learn how this medication performs outside of controlled clinical trials.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Ufa, Bashkortostan Republic, 450054, Russia
Research Site

Kaliningrad, Kaliningrad Oblast, Russia
Research Site

Khabarovsk, Khabarovskiy Kray, 680009, Russia
Research Site

Syktyvkar, Komi, Russia
Research Site

Krasnoyarsk, Krasnoyarsk Region, 660022, Russia
Research Site

Saint Petersburg, Leningradskaya Oblast', 198205, Russia
Research Site

Moscow, Moscow Oblast, 125284, Russia
Research Site

Moscow, Moscow Oblast, 129110, Russia
Research Site

Nizhny Novgorod, Nizhny Novgorod Oblast, Russia
Research Site

Novosibirsk, Novosibirsk Oblast, 630091, Russia
Research Site

Yakutsk, Sakha Republic, 677008, Russia
Research Site

Saratov, Saratov Oblast, 410028, Russia

Conditions

Explore the condition pages connected to this study.

CHRONIC LYMPHOCYTIC LEUKEMIA